Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
Zhang
Lei
L
Lebwohl
David
D
Masson
Eric
E
Laird
Glen
G
Cooper
Michael R
MR
Prince
H Miles
HM
D004305:Dose-Response Relationship, Drug; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D007211:Indoles; D008133:Long QT Syndrome / Q000139:chemically induced*; D000077767:Panobinostat
D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat